India, July 15 -- Mirum Pharmaceuticals Inc. (MIRM) has kicked off the year with commercial growth and successful pipeline milestones, propelling its shares to an all-time high of $53.
The company has three approved ultra-rare medicines and 4 clinical programs. Its marketed drugs include Livmarli oral solution and tablets, Cholbam capsules, and Ctexli tablets.
-- Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older, and progressive familial intrahepatic cholestasis (PFIC) five years of age and older in the U.S. The drug is also approved by the European Commission for the treatment of cholestatic pruritus in patients with ALGS two months and older, and by Health...